Month: May 2020

Phase II CITYSCAPE trial shows promising results adding tiragolumab to Tecentriq in people with PD-L1-positive metastatic non-small cell lung cancerFull results will be presented in an oral abstract session at the ASCO20 Virtual Scientific Program organised by the American Society of Clinical Oncology (ASCO)Basel, 14 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the Phase II CITYSCAPE trial, the first randomised study evaluating the efficacy and safety of tiragolumab plus Tecentriq® (atezolizumab) compared with Tecentriq alone as an initial (first-line) treatment for people with PD-L1-positive metastatic non-small cell lung cancer (NSCLC). Tiragolumab is a novel cancer immunotherapy designed to bind to TIGIT, an immune checkpoint protein expressed on immune cells. Both TIGIT and PD-L1 play an important...

Phase II expansion cohort of “IO-pretreated patients” demonstrates 20% overall response rateData confirm previous preliminary efficacy data seen in this subpopulationInnate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will present new data on its lead partnered asset, monalizumab, at the ASCO20 Virtual Scientific Program being held May 29-31, 2020. The presentation will highlight a Phase II expansion cohort investigating the combination of monalizumab and cetuximab in patients with recurrent or metastatic head and neck squamous cell cancer (R/M SCCHN) who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors (“IO-pretreated”). Monalizumab is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed...

Announces Immediate Appointment of Two New Directors: MG Capital Nominees Kenneth S. Courtis and Michael GorzynskiPreviously Announced Additions Avram A. “Avie” Glazer and Shelly C. Lombard Will Also Begin Serving as Directors Immediately, With Mr. Glazer to Serve as Chairman of the BoardRecent Collaboration With Stockholders Will Result in More Than 50% of the Board Being Refreshed Following the 2020 Annual Meeting MG Capital Agrees to Withdraw its Consent Solicitation and Nomination NoticeNEW YORK, May 14, 2020 (GLOBE NEWSWIRE) — HC2 Holdings, Inc. (“HC2” or the “Company”) (NYSE: HCHC), a diversified holding company, and MG Capital Management, Ltd. (together with Percy Rockdale LLC and Rio Royal LLC, “MG Capital”) today announced a settlement agreement to reconstitute the Board of Directors (the “Board”). The agreement provides...

Publication on May 14, 2020, before market openingRegulated informationEVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR)EVS Q1 2020 Business update

Publication le 14 mai 2020, avant l’ouverture de la bourseInformation réglementéeEVS Broadcast Equipment SA: Euronext Bruxelles (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR).EVS PUBLIE UNE REVUE DE SES ACTIVITÉS AU PREMIER TRIMESTRE 2020EVS, leader mondial de la technologie vidéo en direct pour les productions broadcast et nouveaux médias, annonce aujourd’hui une revue de ses activités pour le premier trimestre se terminant le 31 mars 2020Faits marquantsAcquisition d’Axon annoncée le 1er mai – les synergies devraient apporter entre 6 et 10 millions d’euros d’EBITDA supplémentaires à partir de 2023La crise covid-19 impacte de façon significative les fournisseurs de services en direct qui se préparent à une saison sportive concentréeAugmentation de la demande pour les flux de production à distance permettant...

ORION CORPORATION PRESS RELEASE 14 MAY 2020 at 7.30 EEST                      New ARAMIS Phase III data to be presented at ASCO 2020: Nubeqa® (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancerDarolutamide significantly reduced risk of death by 31 percent (HR=0.69, 95% CI 0.53-0.88; p=0.003) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)Darolutamide significantly delayed the time to pain progression, time to first initiation of cytotoxic chemotherapy, and time to first symptomatic skeletal event (SSE)Darolutamide continues to demonstrate a favorable safety profile, with no new safety signals observed, even with a longer treatment duration, allowing men with nmCRPC to maintain their active lifestyleARAMIS data will be presented at the...

ORION OYJ LEHDISTÖTIEDOTE 14.5.2020 klo 7.30                      Uusia tuloksia ARAMIS Faasi III -tutkimuksesta esitetään ASCO 2020 -kokouksessa: Nubeqa® (darolutamidi) lisäsi merkitsevästi etäpesäkkeetöntä eturauhassyöpää sairastavien miesten kokonaiselinaikaa ja lääkkeellä on suotuisa turvallisuusprofiiliDarolutamidi pienensi merkitsevästi kuoleman riskiä 31 prosentilla (HR=0,69, 95 % CI 0,53-0,88; p=0,003) etäpesäkkeetöntä kastraatioresistenttiä eturauhassyöpää (nmCRPC) sairastavilla miehilläDarolutamidi pidensi merkitsevästi aikaa hoidon aloittamisesta kivun lisääntymiseen, solunsalpaajahoidon aloittamiseen sekä ensimmäiseen oireiseen luustohaittaanDarolutamidilla on suotuisa turvallisuusprofiili eikä uusia turvallisuuteen liittyviä havaintoja tehty pidemmän hoitojakson aikana, mikä mahdollistaa potilaille aktiivisen elämäntavan...

LERØY SEAFOOD GROUP FIRST QUARTER 2020 In Q1 2020, Lerøy Seafood Group (LSG) reported revenue of NOK 5,305 million, compared with NOK 4,746 million in the same period of 2019. Operating profit before fair value adjustment related to biological assets was NOK 816 million in Q1 2020, compared with NOK 691 million in Q1 2019.“In the first quarter of 2020, earnings for the Farming segment and Wild Catch segment were up from Q1 2019, while earnings for the VAPS&D segment were down,” explains CEO Henning Beltestad. He goes on to say: “The Covid-19 pandemic started to have an impact on operations in the first quarter, worsening throughout the first quarter and into the second quarter. I am very proud of the Group’s employees, who have found constructive solutions and displayed a wonderful determination, working extremely hard to keep...

LERØY SEAFOOD GROUP – FØRSTE KVARTAL 2020      Lerøy Seafood Group (LSG) oppnådde en omsetning på MNOK 5.305 i første kvartal 2020, sammenlignet med MNOK 4.746 i samme periode i 2019. Driftsresultat før verdijusteringer knyttet til biologiske eiendeler ble MNOK 816 i første kvartal 2020, sammenlignet med MNOK 691 i første kvartal 2019.I første kvartal 2020 er inntjeningen i Havbruk og Villfangst høyere enn i samme periode i fjor, mens inntjeningen i VAPS&D er lavere, sier konsernleder Henning Beltestad. Gradvis gjennom første kvartal 2020 og videre inn i andre kvartal ble driften betydelig preget av Covid-19 pandemien, forteller Beltestad. Jeg må berømme konsernets ansatte som gjennom konstruktive løsninger og en fantastisk ståpå vilje har jobbet kontinuerlig for å holde konsernets verdikjede åpen og sikre leveranser til våre...

VANCOUVER, British Columbia, May 14, 2020 (GLOBE NEWSWIRE) — Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer is accelerating efforts to service an anticipated increase in demand for both domestic and European markets.As the current COVID-19 health crisis extends into the second quarter of the year, global supply chains for cannabis are facing new challenges to meet growing demands. Licensed North American and European Cannabis operations require significant and ongoing inputs of fertilizers and nutrients along with extensive skilled labour to ensure their timely ability to plant, grow, harvest, test and receive approval to ship at scale in order to service their domestic and international...